Navigation Links
Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
Date:10/25/2007

BOSTON, Oct. 25 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. announced today that it has closed the first tranche of a $40 million private financing. Aisling Capital led the round, with additional participation by new investors, D.E. Shaw and Boston Life Science Venture Corporation, and current investors, Nomura Phase4 Ventures, Novartis BioVentures, BioFund Ventures, HBM BioVentures, Lombard Odier Darier Hentsch, BioVeda Fund and Hercules Technology Growth Capital. The second and final tranche is expected to be closed in early 2008. Pacific Growth Equities served as placement agent for the financing.

Proceeds of the financing will be used primarily to advance Paratek's lead programs to develop broad-spectrum antibiotics, including two antibiotics for the treatment of resistant bacterial infections such as those caused by Methicillin-Resistant Staphylococcus aureus (MRSA). Recent media attention on the dramatic increase in invasive MRSA infections, as published in the October 17, 2007 issue of the Journal of the American Medical Association (JAMA), has highlighted the dire need for new antibiotics to combat these infections in both the hospital and community settings. Paratek has designed two broad- spectrum antibiotics that have been shown to work against susceptible bacteria found in most common infections, as well as antibiotic resistant bacteria such as MRSA, vancomycin-resistant Enterococci (VRE) and penicillin-resistant Streptococcus pneumoniae (PRSP).

Paratek's most advanced broad-spectrum antibiotic, PTK 0796, is currently being developed to treat serious, often life-threatening infections that require a hospital visit such as complicated skin and skin structure infections (cSSSI) and moderate to severe community-acquired pneumonias (CAP). Oral and intravenous (IV) forms of PTK 0796 are being studied in comparison to Zyvox(R) in an ongoing Phase 2 clinical study of patients with cSSSI. The study is anticipated to complete enrollment this
'/>"/>

SOURCE Paratek Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 2014 CTI BioPharma Corp. (CTI) (NASDAQ and ... third quarter 2014 financial results on Wednesday, October 29, ... Following the announcement, members of the management team will ... and provide a general corporate update at 4:30 p.m. ... be obtained as follows: Wednesday, October 29 ...
(Date:10/17/2014)... Oct. 17, 2014  Training market researchers to ... success factor in today,s highly competitive global marketplace. ... organizations that effectively and efficiently produce high performing ... area. Effective training programs can ... recognition from internal clients by developing analysts who ...
(Date:10/17/2014)... DUBLIN , Oct. 17, 2014 ... of the "Research and Development Prospect of ... offering. Based on the 2013 ... Chinese government policies about dialysis industry and the ... in-depth research about dialysis industry segmentations. Moreover, it ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3
... /PRNewswire-Asia/ -- Global Pharm Holdings Group, Inc. ... a China-based, growing vertically integrated pharmaceutical company ... Medicine ("TCM") herbs cultivation and processing business ... and Shandong provinces, today announced that it ...
... Oct. 26, 2011 AtheroNova Inc. (OTCBB: AHRO), a ... compounds to regress atherosclerotic plaque, today announced that it ... the U.S. Food and Drug Administration (FDA). During the ... of AHRO-001, AtheroNova,s lead patent-pending compound for the prevention ...
Cached Medicine Technology:Global Pharm Announces the Closing of US$15 Million Redeemable Convertible Bonds Financing 2Global Pharm Announces the Closing of US$15 Million Redeemable Convertible Bonds Financing 3AtheroNova Completes Successful Pre-IND Meeting with FDA on AHRO-001 2AtheroNova Completes Successful Pre-IND Meeting with FDA on AHRO-001 3
(Date:10/19/2014)... Recently, BambooIndustry.com, one of the most popular suppliers of ... bamboo deckings . Moreover, the company has launched a ... available at deeply discounted rates. , As is ... the significance of online business nowadays. Thus, BambooIndustry.com pays ... workers are striving to deliver both value and efficiency ...
(Date:10/19/2014)... 2014 This report provides comprehensive ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ... features on late-stage and discontinued projects. , Partial ...
(Date:10/19/2014)... 20, 2014 Recently, Top10BestSEOHosting.com has ... that JustHost, GoDaddy and HostMonster are the best ... (Virtual Private Server) is the method of partitioning ... of which has the appearance and capabilities of ... why the site pays close attention to VPS ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses and ... evening dresses . All the company’s old and ... discount is up to 66 percent off. , ... fashion field. Its dress specialists are striving to make ... of the world. All the company’s items are unique, ...
(Date:10/19/2014)... Stephen T. Greenberg, M.D., with offices in Woodbury, Southampton and ... as one of Long Island’s best cosmetic surgeons. In ... the best provider for Botox injections. Glisten, his Skin & ... best Laser Treatment center on Long Island.* , The voting ... the contest once per day, per IP address. , Stephen ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2
... for Pyratine-6(TM) and Pyratine XR(TM)NAPA, Calif., March 31 ... company engaged in the development of technologies that target ... fourth quarter and year ended December 31, 2008. Revenue ... compared with $26,471,000 reported in 2007. Revenues for ...
... DST Systems, Inc. (NYSE: DST ) has ... Systems, Inc. ("Argus"). Argus is now a wholly-owned subsidiary of ... may include forward-looking statements respecting DST and its businesses. Such ... today, and actual actions or results could differ. There could ...
... MSC Care Management, the industry,s ... post-discharge and post-injury workers, compensation claimants nationwide, announced ... Transportation, a national company also focused on the ... position in the market, providing specialized workers, compensation ...
... researchers and private sector biotech scientists will collaborate ... project to discover blood markers that could identify people ... been launched by the Framingham Heart Study. , Researchers ... to Biomarker Research in Cardiovascular Disease, will analyze about ...
... rates to those with the worst marks , , TUESDAY, March ... patients trying to figure out which hospital will provide the ... hospital safety rating conducted by the Leapfrog Group, a nonprofit ... on the safety survey had about the same rate of ...
... Minneapolis-based Courage Center, a nonprofit rehabilitation and resource center, ... , The 2009 Jay ... Center to people with disabilities who have achieved outstanding vocational ... this employment award and receive a $2,000 cash award. , ...
Cached Medicine News:Health News:Senetek PLC Reports 2008 Financial Results 2Health News:Senetek PLC Reports 2008 Financial Results 3Health News:MSC Acquires Optimal Translation & Transportation 2Health News:Effort Could Lead to Blood Tests for Heart Problems 2Health News:Study Casts Doubt on Influential Hospital Safety Survey 2Health News:Study Casts Doubt on Influential Hospital Safety Survey 3Health News:Courage Center Now Accepting Nominations for Jay and Rose Phillips Awards and Phillips Caregiver Award 2
A finely parallel striated (scratched) clear plastic membrane encapsulated between glass plates....
BD Visitec IOL Manipulator (Fenzl), blunt tip angled 45, 12.0 mm from end, fits 0.20 mm diameter holes and larger (3/bx, 1 bx/ca). For positioning intraocular lenses. Sure grip handles hand ridge ind...
... Visitec IOL Manipulator (Jaffe-Maltzman), blunt ... from end, fits 0.20 mm ... positioning intraocular lenses, (3/bx, 1 ... lenses. Sure grip handles hand ...
Sinskey lens manipulator, straight. Also available in titanium....
Medicine Products: